Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7809492 | 0.82 | HSD11B1 (0.45) | KMT2AMEN1HSD11B1ALDH1A1 | |
| SCHEMBL3625928 | 0.82 | MEN1 (0.60) | KMT2AMEN1SLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL29874131 | 0.82 | MEN1 (0.60) | KMT2AMEN1SLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL24108707 | 0.82 | MEN1 (0.43) | KMT2AMEN1SLC22A12HSD11B1 | |
| SCHEMBL856017 | 0.81 | KMT2A (0.55) | KMT2AMEN1SLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL23665026 | 0.80 | MEN1 (0.42) | KMT2AMEN1SLC22A12HSD11B1 | |
| SCHEMBL11217498 | 0.80 | NR1H2 (0.43) | KMT2AMEN1SLC22A12HSD11B1 | |
| SCHEMBL1516275 | 0.80 | MEN1 (0.58) | KMT2AMEN1SLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL27993982 | 0.80 | MEN1 (0.58) | KMT2AMEN1SLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL10292998 | 0.79 | KMT2A (0.53) | KMT2AMEN1SLC22A12HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102321069-B | Preparation method of 2-trifluoromethylthioxanthone | JINAN FUCHUANG MEDICAL TECHNOLOGY CO LTD | 2013-03-20 | — | — | CN | claimed |
| CN-102321069-A | Preparation method of 2-trifluoromethylthioxanthone | JINAN FUCHUANG MEDICAL TECHNOLOGY CO LTD | 2012-01-18 | — | — | CN | claimed |
| EP-1718605-B1 | PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES | WYETH CORP (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2020247054-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-2598511-B1 | NOVEL STABLE AND HIGHLY TUNABLE METATHESIS CATALYSTS | ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES (FR) | 2018-07-04 | — | — | EP | disclosed |
| CN-108026610-A | Method for separating americium from liquid radioactive substances and separating americium from rare earth elements | 俄罗斯国家原子能公司 | 2018-05-11 | — | — | CN | disclosed |
| US-9856254-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-7214698-B2 | Beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-08 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-7186834-B2 | Substituted iminoazines | BAYER AKTIENGESELLSCHAFT (DE) | 2007-03-06 | — | — | US | disclosed |
| US-7186834-B2 | Substituted iminoazines | BAYER AKTIENGESELLSCHAFT (DE) | 2007-03-06 | — | — | US | disclosed |
| CN-1178906-C | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ���Ͽع�����˾ | 2004-12-08 | — | — | CN | disclosed |
| CN-1261876-A | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ABBOTT LAB (US) | 2000-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | KMT2A 2789/4885MEN1 3720/4885SLC22A12 4775/4885 |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | DRD3, DRD2, DRD4 | KMT2A 2239/4885MEN1 4213/4885SLC22A12 1961/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | KMT2A 1449/4885MEN1 3032/4885SLC22A12 4618/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | KMT2A 323/4885MEN1 2716/4885SLC22A12 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.